Main Menu

Dr Albert Antolin

Team Leader

The alt text
Dr Albert Antolin led the Systems Chemical Biology Team. His team aimed to develop public chemical biology resources, uncover how drugs work at a systems level and develop computational methods to design multi-target drugs that tackle cancer drug resistance. Dr Albert Antolin left the ICR in September 2022. Team: Systems Chemical Biology

Biography and research overview 

Dr Albert Antolin became a Team Leader in the Division of Cancer Therapeutics at the Institute of Cancer Research in July 2021.

Dr Albert Antolin is an organic chemist by training (Ramon Llull University, Spain). After working for two years as an in silico medicinal chemist in the pharmaceutical industry, he moved back to academia to pursue a PhD in Pharmacoinformatics (Pompeu Fabra University, Spain). During his PhD, Dr Antolin pioneered the application of polypharmacology prediction to chemical biology by uncovering distantly-related off-targets of chemical probes.

After defending his PhD, Dr Antolin was awarded a prestigious Marie Curie Fellowship to join ICR to develop the first objective, quantitative and data-driven resource for the assessment of chemical probes, Probe Miner. He also actively participated in the development of the cancer translational research and drug discovery knowledgebase canSAR.

Next, Dr Antolin secured the prestigious Sir Henry Wellcome Postdoctoral Fellowship to explore the polypharmacology of cancer drugs and their implications for precision oncology in collaboration with scientists at Columbia University (USA), the Medicines Discovery Catapult (UK) and the Drug Development Unit of ICR and the Royal Marsden Hospital.

Since 2019 to 2022, Dr Antolin also served as the Associate Director of Chemoinformatics at the non-profit Chemical Probes Portal to promote the use of high-quality chemical probes and increase the robustness and reproducibility of biomedical research.

Having worked in industry and academia, Dr Antolin was interested in translational research aiming to bridge applied industrial drug discovery and fundamental questions in cancer chemical systems biology.

Dr Antolin left the ICR in September 2022.